Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...

A medical expert warned of the side effects of the newly launched weight loss drug and advised that the drug should be taken ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an ...

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...